New law may mean harsher exec sentencing

Let's say you're a pharmaceutical company executive. You could still end up in an orange felony jumpsuit if somone in your company violates the Food, Drug & Cosmetic Act--even if you weren't involved, according to a proposed amendment to sentencing laws. Article

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.